Immunoglobulin G4-related sclerosing disease of the paranasal sinus

Head and Neck

Volumn 35, Issue 10, 2013, Pages

  Lindau, Robert H ^a   Su, Yungpo Bernard ^b   Kobayashi, Roger ^b   Smith, Russell B ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Methodist Hospital   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

IgG4 plasma cells; IgG4 sclerosing disease; IgG4 sclerosing disease treatment; paranasal sinus; rituximab

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN G4; PREDNISONE; RITUXIMAB;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DIPLOPIA; DISEASE COURSE; ENDOSCOPY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN G4 RELATED DISEASE; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARANASAL SINUS DISEASE; PARANASAL SINUS IMMUNOGLOBULIN G4 RELATED SCLEROSING DISEASE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

IGG4 PLASMA CELLS; IGG4 SCLEROSING DISEASE; IGG4 SCLEROSING DISEASE TREATMENT; PARANASAL SINUS; RITUXIMAB;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOPSY, NEEDLE; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DECOMPRESSION, SURGICAL; DEXAMETHASONE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MALE; MAXILLARY SINUS; ORBITAL DISEASES; PARANASAL SINUS DISEASES; SCLEROSIS; SEVERITY OF ILLNESS INDEX; SINUSITIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84884906477     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23175     Document Type: Article

References (11)

1. Kamisawa T, Okamoto A,. IgG4-related sclerosing disease. World J Gastroenterol 2008; 14: 3948-3955.
2. Ikeda R, Awataguchi T, Shoji F, Oshima T,. A case of paranasal sinus lesion in IgG4-related sclerosing disease. Otolaryngol Head Neck Surg 2010; 142: 458-459.
3. Ishida M, Hotta M, Kushima R, Shibayama M, Shimizu T, Okabe H,. Multiple IgG4-related sclerosing lesions in the maxillary sinus, parotid gland and nasal septum. Pathol Int 2009; 59: 670-675.
4. Pace C, Ward S,. A rare case of IgG4 related sclerosing disease of the maxillary sinus associated with bone destruction. J Oral Maxillofac Surg 2010; 68: 2591-2593.
5. Khosroshahi A, Bloch DB, Deshpande V, Stone JH,. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62: 1755-1762.
6. Carruthers M, Stone J, Khsroshahi A,. The latest on IgG4-RD: a rapidly emerging disease. Curr Opin Rheumatol 2012; 24: 60-69.
7. Okazaki K, Uchid K, Koyabu M, et al. Recent advances in the concept of autoimmune pacreatitis and IgG4 related disease. Clin Rev Allergy Immunol 2011; 41: 126-138.
8. Lin J, Liebhaber M, Roberts R, Dyer Z, Stiehm R,. Etanercept treatment of cutaneous granulomas in common variable immunodeficiency. J Allergy Clin Immunol 2006; 117: 878-882.
9. Henry C, Deschamps M, Rohrlich PS, et al. Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. Blood 2010: 115: 2420-2429.
10. Sweiss N, Baughman R,. Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon? J Rheumatol 2007; 34: 2129-2131.
11. Renaudineau Y, Devauchelle-Pensec V, Hanrotel C, Pers JO, Saraux A, Youinou P,. Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects. Joint Bone Spine 2009; 76: 458-463.